Methoctramine an M2 muscarinic receptor antagonist, may represent a lead compound to design new therapeutic agents accelerating heart rate without concomitant side-effects on other parasympathetically innervated organs.
Methoctramine
QUAGLIA, Wilma;
1989-01-01
Abstract
Methoctramine an M2 muscarinic receptor antagonist, may represent a lead compound to design new therapeutic agents accelerating heart rate without concomitant side-effects on other parasympathetically innervated organs.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.